Literature DB >> 7873374

Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells.

R Dengler1, U Münstermann, S al-Batran, I Hausner, S Faderl, C Nerl, B Emmerich.   

Abstract

Proteinase 3 (P3) is a serine proteinase present in the primary granules of neutrophils. We have investigated the expression of this protein in samples of bone marrow from healthy individuals and patients with different types of leukaemias by using immunocytochemical staining and flow cytometric quantitation. In normal bone marrow the enzyme was found in promyelocytes, myelocytes, metamyelocytes, band forms and polymorphonuclear neutrophils, correlating with the synthesis of neutrophil serine proteinases during myeloid maturation. No staining was found within the lymphoid, erythroid and megakaryocytic lineage. In the leukaemic samples, only those of acute myeloid and chronic myeloid leukaemia patients were labelled with the antiproteinase 3 antibody. Cases of acute lymphoblastic and chronic lymphocytic leukaemia, as well as other malignant lymphomas, were consistently negative, indicating that P3 may be used as a specific marker for the discrimination between myeloid and lymphoid leukaemias. In addition, immunoreactivity of myeloperoxidase (MPO) was investigated and the expression of P3 and MPO correlated with the French-American-British (FAB) classification. P3 was not detected in minimally differentiated M0 and M1 cases but was in predominantly labelled cells of M2 and M3 subtypes plus half of the M4 and one out of six M5 cases but not those of M6. These findings correspond to the differentiation stage in which P3 is expressed and stored in the primary granules. Therefore the enzyme may also be used as an adjunct to the classic morphological and cytochemical methods to elucidate further the stage at which the differentiation arrest of the leukaemic clone has occurred.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7873374     DOI: 10.1111/j.1365-2141.1995.tb03297.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Authors:  Tian-Hui Yang; Lisa S St John; Haven R Garber; Celine Kerros; Kathryn E Ruisaard; Karen Clise-Dwyer; Gheath Alatrash; Qing Ma; Jeffrey J Molldrem
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

Review 4.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

5.  Characterization of chronic myeloid leukemia stem cells.

Authors:  Jonathan M Gerber; Lu Qin; Jeanne Kowalski; B Douglas Smith; Constance A Griffin; Milada S Vala; Michael I Collector; Brandy Perkins; Marianna Zahurak; William Matsui; Christopher D Gocke; Saul J Sharkis; Hyam I Levitsky; Richard J Jones
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

6.  Myeloblastin is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells.

Authors:  P G Lutz; C Moog-Lutz; E Coumau-Gatbois; L Kobari; Y Di Gioia; Y E Cayre
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 7.  Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Authors:  A J Barrett; K Rezvani
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

8.  MCF-7 mammary tumour cells express the myeloid cell differentiation controlling factor, serine protease 3/myeloblastin.

Authors:  S Horman; D Fokan; P Galand
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

9.  Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome.

Authors:  Lu Jiang; Xue-Ping Li; Yu-Ting Dai; Bing Chen; Xiang-Qin Weng; Shu-Min Xiong; Min Zhang; Jin-Yan Huang; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

10.  PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.

Authors:  Lisa S St John; Liping Wan; Hong He; Haven R Garber; Karen Clise-Dwyer; Gheath Alatrash; Katayoun Rezvani; Elizabeth J Shpall; Catherine M Bollard; Qing Ma; Jeffrey J Molldrem
Journal:  Cytotherapy       Date:  2016-08       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.